-
SABCS Expert Commentary | Professor Mao Xiaoyun: The ALTTO Study Confirms Superior DFS With Aromatase Inhibitors Over SERMs, Providing New Evidence for Endocrine Therapy in HR+/HER2+ Breast Cancer
In patients with HR-positive/HER2-positive early breast cancer, adjuvant anti-HER2 therapy constitutes the cornerstone of systemic treatment. However, robust high-level evidence has long been lacking to guide the choice between aromatase inhibitors (AIs) and tamoxifen (SERMs) for adjuvant endocrine therapy in this population.
-
SABCS Expert Commentary | Professor Wang Xin: ctDNA Clearance Predicts pCR in HER2-Positive Breast Cancer and Supports Precision De-escalation Strategies
De-escalation therapy has become an important trend in the management of HER2-positive early breast cancer, yet accurately identifying patients who can safely omit chemotherapy remains a major challenge. At the 2025 San Antonio Breast Cancer Symposium (SABCS), the PHERGuide substudy innovatively incorporated circulating tumor DNA (ctDNA) monitoring into the neoadjuvant treatment framework. The study demonstrated…
-
Professor Andrea Necchi: Precision Patient Selection and Recurrence Control—Key Challenges on the Bladder-Sparing Pathway
| 15th Shanghai Urologic Oncology Academic ConferencePlay Editor’s Note: With the continuous evolution of treatment concepts and the advancement of therapeutic strategies, the management landscape of muscle-invasive bladder cancer (MIBC)…
-
Efficient Androgen Receptor Blockade, Survival Benefit, and Precision Stratification in Clinical Practice
| The 15th Shanghai Urologic Oncology Academic Conference Editor’s Note: The 15th Shanghai Urologic Oncology Academic Conference was held in Pudong, Shanghai, bringing together leading experts in urologic oncology from…
-
China Voice at SABCS | Prof. Liu Yunjiang: ⁶⁸Ga-HER2 PET/CT for Early pCR Prediction in HER2+ Breast Cancer
Editor’s Note: De-escalation and precision tailoring of neoadjuvant therapy have become major trends in the management of HER2-positive early breast cancer, yet accurately predicting pathological response at an early stage…
-
Professor Ma Fei: nab-sirolimus Brings a New Breakthrough for HR+/HER2− Advanced Breast Cancer in the Post-CDK4/6 Inhibitor Era
Editor’s Note: The 48th San Antonio Breast Cancer Symposium (SABCS 2025) recently concluded successfully in San Antonio, USA. At the meeting, Professor Ma Fei and his team from the Cancer…
-
Voices from China at SABCS | Professor Biyun Wang:
ER Loss Requires Vigilance—Evidence Shows Poor Prognosis in Patients with ER Positive-to-Negative Conversion** Editor’s Note:Estrogen receptor (ER)–positive breast cancer has traditionally been regarded as a relatively indolent subtype. However, during…
-
Voices from China at SABCS | Professor Yongmei Yin’s Team Reports Chemotherapy-Free Neoadjuvant RC48 Plus Pyrotinib Regimen Achieving Breakthrough pCR
Editor’s Note: At the 2025 San Antonio Breast Cancer Symposium (SABCS), the team led by Professor Yongmei Yin from the First Affiliated Hospital of Nanjing Medical University / Jiangsu Province…
Connecting Medical Expertise through Media